Dr Reddy’s Takes Another Step Forward On Tocilizumab
IV Version Of Indian Firm’s Actemra/RoActemra Biosimilar Completes Phase I Study
Dr Reddy’s has notched up another achievement for its biosimilar tocilizumab candidate, after the intravenous presentation of the firm’s proposed Actemra/RoActemra rival completed a Phase I study.
